Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-M61SQ in Relapsed/Refractory Multiple Myeloma
NCT06888752Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Mar 2025
- Primary completion
- Jun 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of LCAR-M61SQ in multiple myeloma (MM), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Dose-limiting toxicity rate at 30 days, Treatment-emergent adverse events at 2 years and 5 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
LCAR-M61SQ
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06888752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888752.